6MNY

Crystal structure of mouse BTK kinase domain in complex with compound 9a


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.257 
  • R-Value Work: 0.196 
  • R-Value Observed: 0.199 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.

Schnute, M.E.Benoit, S.E.Buchler, I.P.Caspers, N.Grapperhaus, M.L.Han, S.Hotchandani, R.Huang, N.Hughes, R.O.Juba, B.M.Kim, K.H.Liu, E.McCarthy, E.Messing, D.Miyashiro, J.S.Mohan, S.O'Connell, T.N.Ohren, J.F.Parikh, M.D.Schmidt, M.Selness, S.R.Springer, J.R.Thanabal, V.Trujillo, J.I.Walker, D.P.Wan, Z.K.Withka, J.M.Wittwer, A.J.Wood, N.L.Xing, L.Zapf, C.W.Douhan III, J.

(2019) ACS Med Chem Lett 10: 80-85

  • DOI: 10.1021/acsmedchemlett.8b00461
  • Primary Citation of Related Structures:  
    6MNY

  • PubMed Abstract: 
  • Potent covalent inhibitors of Bruton's tyrosine kinase (BTK) based on an aminopyrazole carboxamide scaffold have been identified. Compared to acrylamide-based covalent reactive groups leading to irreversible protein adducts, cyanamide-based reversible-covalent inhibitors provided the highest combined BTK potency and EGFR selectivity ...

    Potent covalent inhibitors of Bruton's tyrosine kinase (BTK) based on an aminopyrazole carboxamide scaffold have been identified. Compared to acrylamide-based covalent reactive groups leading to irreversible protein adducts, cyanamide-based reversible-covalent inhibitors provided the highest combined BTK potency and EGFR selectivity. The cyanamide covalent mechanism with BTK was confirmed through enzyme kinetic, NMR, MS, and X-ray crystallographic studies. The lead cyanamide-based inhibitors demonstrated excellent kinome selectivity and rat pharmacokinetic properties.


    Organizational Affiliation

    Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Tyrosine-protein kinaseA, B276Mus musculusMutation(s): 0 
Gene Names: Btk
EC: 2.7.10.2
UniProt & NIH Common Fund Data Resources
Find proteins for Q7TMU1 (Mus musculus)
Explore Q7TMU1 
Go to UniProtKB:  Q7TMU1
IMPC:  MGI:88216
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
JVP (Subject of Investigation/LOI)
Query on JVP

Download Ideal Coordinates CCD File 
C [auth A]5-amino-1-[(3R)-1-cyanopiperidin-3-yl]-3-[4-(2,4-difluorophenoxy)phenyl]-1H-pyrazole-4-carboxamide
C22 H20 F2 N6 O2
SQFDBQCBXUWICP-OAHLLOKOSA-N
 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
JVP BindingDB:  6MNY IC50: min: 1.3, max: 17.3 (nM) from 3 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.80 Å
  • R-Value Free: 0.257 
  • R-Value Work: 0.196 
  • R-Value Observed: 0.199 
  • Space Group: P 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 37.945α = 76.77
b = 63.515β = 85.27
c = 70.005γ = 78.13
Software Package:
Software NamePurpose
BUSTERrefinement
HKL-2000data reduction
SCALAdata scaling
BUSTERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2019-01-30
    Type: Initial release